Cosmos Health (COSM) Research & Development (2024 - 2025)
Cosmos Health (COSM) recorded quarterly Research & Development of $410760.0 in Q4 2025, up 2140.06% on a QoQ basis from $18337.0 in Q3 2025, and down 22.98% year-over-year from $533293.0 in Q4 2024.
Cosmos Health (COSM) Research & Development (2024 - 2025) Analysis & Trends
Cosmos Health has disclosed Research & Development across 2 years of filings, most recently posting $410760.0 for Q4 2025.
- Quarterly Research & Development fell 22.98% year-over-year to $410760.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $503734.0 (down 8.23% YoY) and the FY2025 annual result came in at $519363.0, down 2.61% from the prior year.
- Research & Development climbed to $410760.0 in Q4 2025, from $18337.0 in the prior quarter.
- Over five years, Research & Development peaked at $533293.0 in Q4 2024 and troughed at $15629.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - | - |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn | - |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn | - |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn | - |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn | - |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn | - |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn | 2.60 Mn |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn | -2.11 Mn |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn | - |
| 10 | Cellyan Biotechnology | 5.69 | -2.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 410,760.00 |
| Sep 30, 2025 | 18,337.00 |
| Jun 30, 2025 | 74,637.00 |
| Mar 31, 2025 | 15,629.00 |
| Dec 31, 2024 | 533,293.00 |